

CLAIMS

- 1) Device intended for the transdermic administration of an active ingredient (I) and an active ingredient (II), constituted by two compartments (A) and (B),
- compartment (A) containing an adhesive polymer matrix loaded with active ingredient (I), to which one or more additives can optionally be added,
 - and compartment (B) containing an adhesive polymer matrix loaded with active ingredient (II), to which one or more additives can optionally be added, each of these matrices being rapidly covered with a protective film (a) and (a') identical or different, characterised in that compartment (A) is separated from compartment (B) by an empty space of between 1 and 10 mm and characterised in that compartments (A) and (B) are supported by the same peel-off protective film (b).
- 2) Device intended for transdermic administration according to claim 1, characterised in that compartment (A) contains a progestomimetic compound and compartment (B) contains an oestrogen compound.
- 3) Device according to claim 2, characterised in that the progestomimetic is selected from the following components: norethindrone (17 α)-17-hydroxy-19-norpregn-4-en-20-yne-3-one, norgestimate (17 α)-17-(acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one-3-oxyme, norgesterone (17 α)-17-hydroxy-19-norpregna-5(10),20-dien-3-one, Trimegestone 17 α -methyl-17 β -(2-hydroxy-1-oxo-propyl)-estra-4,9-dien-3-one (21S), promegestone (17 β)-17-methyl-17-(1-oxopropyl)estra-4,9-dien-3-one, Levonorgestrel Form (-) of 13-ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one (norgestrel), ST 1435 16-

methylene-17 α -acetoxy-19-nor-4-pregnene-3,20-dione,
 Medroxyprogesterone (6 α)-17-hydroxy-6-methylpregn-4-ene-
 3,20-dione, Gestodene (17 α)-13-ethyl-17-hydroxy-18,19-
 dinorpregna-4,15-dien-20-yn-3-one, Dienogest 17-hydroxy-3-
 5 oxo-19-nor-17 α -pregna-4,9-diene-21-nitrile, Desogestrel
 (17 α)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-
 17-ol, Ketodesogestrel (17 α)-13-ethyl-11-methylene-18,19-
 dinorpregn-4-en-20-yn-3-one-17-ol, Norethisterone acetate
 (17 α)-17-acetoxy-19-norpregn-4-en-20-yn-3-one, Demegestone
 10 17-methyl-19-norpregna-4,9-diene-3,20-dione and
 combinations of these compounds.

- 4) Device according to one of claims 2 and 3,
 characterised in that the progestomimetic compound is
 Trimegestone.
- 15 5) Device according to claim 2, characterised in that
 the oestrogen compound is selected from the following
 compounds: 17-beta-oestradiol, ethynyl oestradiol,
 oestrone and oestrogen of "equine origin" such as
 Premarin® and combinations of these compounds.
- 20 6) Device according to one of claims 2 and 5,
 characterised in that the oestrogen compound is 17-beta-
 oestradiol.
- 7) Device according to any one of claims 1 to 6, in
 which:
- 25 - compartment (A) contains a mono-layer matrix constituted
 by a silicone polymer, loaded with Trimegestone and
 optionally a plasticizer
- and compartment (B) contains a mono-layer matrix
 constituted by a 2-ethylhexyl acrylate and vinyl acetate
 30 copolymer, loaded with oestradiol and optionally a
 hydrophilic polymer.

8) Device according to any one of claims 1 to 6, in which:

- compartment (A) contains a two-layer matrix

a) the first layer being constituted by a silicone

5 polymer loaded with Trimegestone,

b) the second layer, the layer that adheres to the skin, also being constituted by a silicone polymer.

- and compartment (B) contains a mono-layer matrix constituted by a 2-ethylhexyl acrylate and vinyl acetate
10 copolymer, loaded with oestradiol and optionally a hydrophilic polymer.

9) Manufacturing process for the devices according to claims 1 to 8, characterised in that:

Stage I: for the manufacture of the patch corresponding to
15 compartment (A)

1 - the silicone adhesive polymer layer loaded with active ingredient (I) and optionally one or more additives such as a hydrophilic polymer, an absorption promoter or a plasticizer is coated on the protective film (a),

20 2 - the solvent is evaporated until the "matrix loaded with active ingredient (I)/protective film (a)" set corresponding to compartment (A) is obtained,

3 - the "matrix loaded with active ingredient (I)/protective film (a)" set is colaminated on the peel-
25 off protective film (b'),

4 - a patch of 5 to 50 cm² is cut out.

Stage II: for the manufacture of the patch corresponding to compartment (B)

1 - the adhesive polymer layer loaded with active
30 ingredient (II) and optionally one or more additives such as a hydrophilic polymer, an absorption promoter or a plasticizer is coated on the protective film (a'),

2 - the solvent is evaporated until the "matrix loaded with active ingredient (II)/protective film (a') " set corresponding to compartment (B) is obtained,

3 - the "matrix loaded with active ingredient (II)/protective film (a) " set is colaminated on the peel-off protective film (b''),

4 - a patch of 5 to 50 cm² is cut out.

Stage III: for the manufacture of the "bipatch"

1 - the peel-off protective film (b') is peeled from the patch obtained in Stage I,

2 - the "matrix loaded with active ingredient (I)/protective film (a) " set is transferred to the peel-off protective film (b),

3 - the peel-off protective film (b'') is peeled from the patch obtained in Stage II,

4 - the matrix loaded with "active ingredient (II)/protective film (a') " set is then transferred to the previous peel-off protective film (b), respecting a distance of 1 to 10 mm between compartments (A) and (B).

10) Device according to any one of claims 1 to 8 for use in a process for delivering several medicaments by applying the two matrices of the device to the said patient's skin or mucous membranes.